Glaucoma

The campaign provides tools to patients, researchers, clinicians, industry, and advocates with tools to tell their stories that advocate for vision research.

Nicox’s nitric oxide (NO)-donating bimatoprost eye drop works to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

From blue light blockers to sleep apnea, Jacqueline Theis, OD, FAAO, FNAP; and Joseph Allen, OD, FAAO, Dipl ABO, outlined how sleep can influence brain and ocular health, and vice versa.

The DSLT technology has been fully commercially available in the US since February 2025.

New clinical trials reveal PER-001 as a groundbreaking treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.

The Innovation Hub was split into 3 panel discussions on assessing future health through AI-enabled tools, addressing patient workflow challenges through AI, and enhancing treatment through new technologies.

A $2.5 million endowment establishes the Herbert Simon Chair in Glaucoma Research and Innovation, advancing treatments and research led by renowned glaucoma researcher Alon Harris, PhD, MS, FARVO.

This new QLS-111 and latanoprost fixed-dose combination (QLS-111-FDC; Qlaris) is in development for the treatment of primary open-angle glaucoma, ocular hypertension, and normal-tension glaucoma in patients whose optimal intraocular pressure control may remain “unachievable” due to needing to lower episcleral venous pressure.

The study was an outgrowth of the phase 1 and 2 Ocular Hypertension Treatment Study (OHTS).

The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1310 nm that can scan at a speed of 50,000 A-scan/second.

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).

Knowing the truths concerning patient adherence and history and visual field tests can make a difference in care quality.

The first-in-class endothelin antagonist intravitreal implant aided in increasing ocular blood flow and improved both visual function and anatomic structure, according to the company.

The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.

Results from the first-in-human study of SpyGlass Pharma's bimatoprost-eluting IOL showed significant reduction in IOP and improved best-corrected distance visual acuity.

STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long term safety and efficacy of MINIject in patients with up to 5 years of follow up.

The starry faculty has a galaxy of symposia planned for May 4, 2025.

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts in the Qassim region of Saudi Arabia.

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

Deborah Ristvedt, DO, and Melissa Tawa, OD, FAAO, detail the benefits of interventional glaucoma during their CRU 2025 presentation.

The new service will work to reduce waiting times for glaucoma assessments, monitoring, and treatment.

If executed, the reverse merger would create a new ophthalmic company that pairs two FDA-approved technologies for use in glaucoma patients.

The retrospective cohort study included adults with POAG from 12 tertiary-care health systems participating in the SOURCE Ophthalmology Big Data consortium in the US.

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

The Preservative Freedom Coalition’s recent Glaucoma Patient Experience survey also found a need to better communication between patients and eye care providers.

The study, published in JAMA Network Open, found that only 8.2% of patients who were referred and received a glaucoma evaluation were diagnosed with glaucoma.

Researchers set out to determine the age groups for which a polygenic risk score would most effectively predict glaucomatous risk and help inform cost-effective methods for disease detection.

Key parameters captured by the module include disc area, cup area, cup volume, minimal cup depth, maximum cup depth, cup/disc area ratio, rim absence angle, and disc-damage likelihood scale.

NCX 470 0.1% achieved an intraocular pressure of less than or equal to 18 mmHg compared to latanoprost 0.005% in the trial.

Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.